<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04721249</url>
  </required_header>
  <id_info>
    <org_study_id>AS-2124</org_study_id>
    <nct_id>NCT04721249</nct_id>
  </id_info>
  <brief_title>D-serine Supplementation for Depression</brief_title>
  <official_title>A Randomized add-on Trial of D-serine for Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>André Schmidt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Psychiatric Hospital of the University of Basel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The glutamate system is emerging as target for the development of novel antidepressant&#xD;
      medication, in particular compounds modulating the NMDA receptor. While the NMDA receptor&#xD;
      antagonist ketamine is an effective option for many treatment-restistant patients, it is also&#xD;
      accompanied by dissociative and cognitive effects and also bears the risk to develop&#xD;
      addiction, side effects that are significantly restricting its clinical utility. There is now&#xD;
      compelling evidence of the antidepressant potential of D-serine, a NMDAR co-agonist. Compared&#xD;
      to ketamine, D-serine goes along without any psychotomimetic effects or other side effects&#xD;
      and thus might be a prom-ising novel antidepressant.&#xD;
&#xD;
      This study represents the first randomized control trial to test the efficacy of D-serine as&#xD;
      an adjuvant therapy in patients with depression and thereby adds to re-cent efforts to&#xD;
      establish novel glutamatergic antidepressants. Besides clinical measures, this study also&#xD;
      explores the biological mechanisms underlying D-serine's clinical effect.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Depression Severity</measure>
    <time_frame>Change from baseline HAM-D score at 6 weeks</time_frame>
    <description>measured with the Hamilton Depression Rating Scale (HAM-D)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>Change from baseline STAI score at 6 weeks</time_frame>
    <description>measured with the State-and Trait-Anxiety Inventory (STAI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anhedonia</measure>
    <time_frame>Change from baseline SHAPS score at 6 weeks</time_frame>
    <description>measured with the Snaith-Hamilton-Pleasure Scale (SHAPS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognition</measure>
    <time_frame>Change from baseline VLMT score at 6 weeks</time_frame>
    <description>measured with the Verbal Learning and Memory Test (VLMT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prefrontal glutamate concentration</measure>
    <time_frame>Change from baseline glutamate level at 6 weeks</time_frame>
    <description>measured with magnetic resonance spectroscopy (MRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress level</measure>
    <time_frame>Change from baseline cortisol level at 6 weeks</time_frame>
    <description>measured with Cortisol awakening responses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>Change from baseline interleukin 1 and 6 level at 6 weeks</time_frame>
    <description>measured with the blood levels of interleukin 1 and 6</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Verum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>D-serine</intervention_name>
    <description>Patients will receive four 500mg capsules of D-serine each day over a course of six weeks (two after breakfast and two after dinner).</description>
    <arm_group_label>Verum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients in the placebo group will receive four placebo capsules each day (two after breakfast and two after dinner). The placebo capsules will contain Mannotol / Mannitol-Silica (99.5/0.5, respectively) and will be indistinguishable from D-serine by matching colour, shape, size and packaging.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-60&#xD;
&#xD;
          -  Inpatients with a diagnosis of MDD with a current moderate-to-severe episode (HAM-D&#xD;
             score &gt; 16) (7)&#xD;
&#xD;
          -  Treatment as usual (TAU) for depression. TAU for depression may include no treatment&#xD;
             at all or standard pharmacotherapy (antidepressants and antipsychotics such as&#xD;
             aripiprazole, risperidone or quetiapine) and / or psychotherapy.&#xD;
&#xD;
          -  Able to read and understand study procedures and participant's information&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other primary psychiatric diagnoses than MDD such as substance use and psychotic&#xD;
             disorders&#xD;
&#xD;
          -  Serious suicide attempts&#xD;
&#xD;
          -  Contradiction for MRI (no pacemaker, MRI incompatible metal implants or splinters in&#xD;
             the body, past heart/head surgery, past stroke/brain injury, claustrophobia)&#xD;
&#xD;
          -  Pregnant or lactating women (pregnancy test)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>André Schmidt, PD Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Basel, Department of Psychiatry (UPK)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>André Schmidt, PD Dr</last_name>
    <phone>+41 (0)61 325 59 29</phone>
    <email>andre.schmidt@unibas.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Basel, Department of Psychiatry (UPK)</name>
      <address>
        <city>Basel</city>
        <state>Baselstadt</state>
        <zip>4002</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>André Schmidt, PD Dr</last_name>
      <phone>+41 (0)61 325 59 29</phone>
      <email>andre.schmidt@unibas.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 15, 2021</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Psychiatric Hospital of the University of Basel</investigator_affiliation>
    <investigator_full_name>André Schmidt</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

